Telix: A masterclass in what this game is all about

Today's market darling reminds us why we love to invest. But is it too late?

| More on:
A boy is excited because he won the computer game.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Every now and again, an ASX company emerges that captures the hearts and minds of investors. 

It doesn't happen every year, but it certainly happens more often than you think. 

From Droneshield (ASX: DRO) to ProMedicus (ASX: PME) to Supply Network (ASX: SNL), these companies have all produced total returns in excess of 700% over the last 5 years. 

The latest market darling is, of course, none other than Telix Pharmaceuticals (ASX: TLX). 

Just 5 years ago, the company reported revenue of $3.5m and now its 2025 sales guidance is in excess of $1.2 billion (US$785m at the midpoint), a phenomenal 343x increase! 

Its share price has done alright, just a lazy 25x increase over the same period. 

It's the stuff that dreams are made of, and it reminds us why we love this game of investing. 

Now, if you cut out the hype, there are actually important investing lessons to learn from Telix.

Stay optimistic and always look forward 

Five years ago, we were in the midst of a pandemic, and the world was facing a lot of uncertainty. (Not much has changed!). 

It would have been easy to ignore a small, speculative pharmaceutical company with $3.5m in revenue, but investing is all about looking ahead, imagining all the different possibilities, and pricing them accordingly. 

No matter what the headlines say, the share market will surprise you with the opportunities that it can create. Stay optimistic, always look forward. 

Business fundamentals matter

A 25x share price return is nice, but the real story here is the 343x increase in sales. Students of the game know how important it is to study the business and its fundamentals. 

The context matters too. Sales growth may be important for Telix now as a growth company, but perhaps at some point in the future, earnings per share and free cash flow will become more important metrics. 

Tough times will come 

Sorry to be the bearer of bad news, but tough times will eventually come. At some point, Telix shareholders will have to deal with a major share price decline. It could be up to a 20% decline, or it could be a lot more. 

It happens to every market darling, and it's just the nature of the beast. 

The time to mentally prepare yourself and work out what you would do in such a scenario is now. Write down your game plan, explain your rationale, and constantly re-evaluate it using the business fundamentals as your guide. Tough times will eventually come. 

You don't need a Telix to do well

Telix's monster returns are worth celebrating; this is a company solving real-world problems after all. But let me be clear: you don't need Telix to do well in the share market. 

I say this because it's natural for investors who have missed out on Telix to have that fear of missing out (FOMO). If that's you, remember that there are plenty of opportunities out there. 

They won't all do as well as Telix, but even a 2x return in 5 years (just short of a 15% compounded annual growth rate) is a great return. 

Find the next Telix 

Finally, it's of no use to just look back at Telix's success without applying the lessons to help us find the next Telix. Ultimately, finding winning companies is what this game is all about. That's why we love it. 

If you need some help doing that, I know a band of merry Fools who just might be able to help…

Motley Fool contributor Kevin Gandiya has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended DroneShield, Supply Network Ltd, and Telix Pharmaceuticals. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus, Supply Network Ltd, and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Winning woman smiles and holds big cup while losing woman looks unhappy with small cup
Share Gainers

Here are the top 10 ASX 200 shares today

It was a happy hump day for ASX shares.

Read more »

Man presses green buy button and red sell button on a graph.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Share Gainers

Why EBR Systems, Endeavour, Monadelphous, and Neuren shares are racing higher today

These shares are having a good session on Wednesday. But why?

Read more »

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Share Fallers

Why EOS, Humm, Pantoro Gold, and Robex shares are dropping today

These shares are having a tough time on hump day. But why?

Read more »

A woman in a business suit sits at her desk with gold bars in each hand while she kisses one bar with her eyes closed. Her desk has another three gold bars stacked in front of her. symbolising the rising Northern Star share price
Gold

Titan Minerals shares leaping 14% on Wednesday on 'spectacular' gold results

Investors are piling into Titan Minerals shares today following 'phenomenal' gold exploration results.

Read more »

Male hands holding Australian dollar banknotes, symbolising dividends.
Share Market News

BlueScope returns $438m to shareholders with special dividend

BlueScope will return $438 million to shareholders via a $1 per share special dividend after selling major assets.

Read more »

Man looking happy and excited as he looks at his mobile phone.
Broker Notes

Want silver exposure? Morgans says this ASX silver stock is a buy

The broker thinks this could be a high-risk, high-reward option for investors.

Read more »

CEO of a company talking.
Share Market News

Deep Yellow welcomes new CEO as part of ongoing uranium growth strategy

Deep Yellow has set a start date for new CEO Greg Field, with project development remaining on track as part…

Read more »